---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-280212"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:12:47.496853+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Phase 2 GBM trial: mOS 13 mo (63% above SOC), mPFS 11 mo

## Summary
- Median overall survival 13 months in 15 rGBM patients, 63% better than SOC bevacizumab (8 mo).
- Median progression-free survival 11 months vs SOC 4 months; 9 of 15 patients remain alive.
- Delivers up to 20x radiation dose (740 Gy) vs EBRT (35 Gy); favorable safety profile maintained.
- Imaging analysis confirms efficacy signal; company to host KOL webinar Nov 20 at 10 am ET.

## SEC filing metadata
- accession: 0001193125-23-280212
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312523280212/0001193125-23-280212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312523280212/d620464d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-280212
- JSON: https://secwatch.observer/filing/0001193125-23-280212.json
- Plain text: https://secwatch.observer/filing/0001193125-23-280212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.